Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY)’s Stock Is Buy After Less Market Selling

November 14, 2017 - By Richard Conner

 Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY)'s Stock Is Buy After Less Market Selling

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.70, from 0.82 in 2017Q1. It improved, as 24 investors sold Alnylam Pharmaceuticals, Inc. shares while 49 reduced holdings. 49 funds opened positions while 62 raised stakes. 85.40 million shares or 6.40% more from 80.26 million shares in 2017Q1 were reported.
Wells Fargo And Communication Mn owns 329,616 shares or 0.01% of their US portfolio. Baillie Gifford & holds 0.37% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 3.43 million shares. Ecor1 Ltd Liability Co holds 10,425 shares. Victory Cap Mngmt has 26,025 shares for 0% of their portfolio. Tci Wealth Inc holds 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 11 shares. Pub Employees Retirement Association Of Colorado stated it has 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Evercore Wealth Llc owns 600 shares or 0% of their US portfolio. Farallon Cap Management Ltd Limited Liability Company invested in 200,000 shares or 0.17% of the stock. Verition Fund Management Ltd Limited Liability Company invested in 0.1% or 13,296 shares. Moreover, Commonwealth Equity Services Inc has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bb Biotech Ag reported 1.22M shares stake. Teacher Retirement Sys Of Texas invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 7,620 were reported by Hanseatic Mngmt. First Personal Financial has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 219 shares. Soros Fund Mgmt Ltd invested in 7,000 shares or 0.01% of the stock.

Since May 15, 2017, it had 2 buys, and 1 sale for $21.31 million activity. Mason Michael had sold 9,375 shares worth $656,250. KEATING LAURIE bought $751,502 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, May 30. On Wednesday, May 31 Sanofi bought $21.38 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 297,501 shares.

The stock of Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) registered a decrease of 7.97% in short interest. ALNY’s total short interest was 5.81M shares in November as published by FINRA. Its down 7.97% from 6.32 million shares, reported previously. With 1.05 million shares average volume, it will take short sellers 6 days to cover their ALNY’s short positions. The short interest to Alnylam Pharmaceuticals Incorporated’s float is 8.18%.

About 2.27 million shares traded or 97.39% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since November 14, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $11.90 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 83 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Leerink Swann given on Tuesday, February 16. Stifel Nicolaus maintained it with “Hold” rating and $36 target in Thursday, October 6 report. The firm has “Outperform” rating given on Tuesday, May 3 by Leerink Swann. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, September 8 report. As per Friday, August 28, the company rating was maintained by JMP Securities. As per Thursday, August 10, the company rating was maintained by BMO Capital Markets. The firm has “Buy” rating given on Friday, October 23 by Jefferies. On Wednesday, November 30 the stock rating was maintained by Chardan Capital Markets with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Thursday, September 21 by Cowen & Co. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by FBR Capital on Thursday, October 6.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Nasdaq.com which released: “Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA” on November 14, 2017, also Nasdaq.com with their article: “Fayerweather Charles Buys DowDuPont Inc, Alnylam Pharmaceuticals Inc, Fortive …” published on October 27, 2017, Seekingalpha.com published: “Alnylam Pharmaceuticals Wins Another Round” on November 02, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Businesswire.com and their article: “Alnylam Pharmaceuticals Prices Public Offering of Common Stock” published on November 14, 2017 as well as Seekingalpha.com‘s news article titled: “Alnylam Pharmaceuticals (ALNY) Q3 2017 Results – Earnings Call Transcript” with publication date: November 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.